Marfan syndrome (MFS) is an autosomal dominant disorder of connective tissue, caused by mutations of the microfibrillar protein fibrillin-1, that predisposes affected individuals to aortic aneurysm and rupture and is associated with increased TGFβ signaling. TGFβ is secreted from cells as a latent complex consisting of TGFβ, the TGFβ propeptide, and a molecule of latent TGFβ binding protein (LTBP). Improper extracellular localization of the latent complex can alter active TGFβ levels, and has been hypothesized as an explanation for enhanced TGFβ signaling observed in MFS. We previously reported the absence of LTBP-3 in matrices lacking fibrillin-1, suggesting that perturbed TGFβ signaling in MFS might be due to defective interaction of latent TGFβ complexes containing LTBP-3 with mutant fibrillin-1 microfibrils. To test this hypothesis, we genetically suppressed Ltbp3 expression in a mouse model of progressively severe MFS.
Here, we present evidence that MFS mice lacking LTBP-3 have improved survival, essentially no aneurysms, reduced disruption and fragmentation of medial elastic fibers, and decreased Smad2/3 and Erk1/2 activation in their aortas. These data suggest that, in MFS, improper localization of latent TGFβ complexes composed of LTBP-3 and TGFβ contributes to aortic disease progression. extracellular matrix | transforming growth factor beta | aneurysm | LTBP M arfan syndrome (MFS) is an autosomal dominant connective tissue disorder caused by mutations in the gene encoding fibrillin-1 (FBN1), an extracellular matrix (ECM) glycoprotein that is the main component of microfibrils and that associates with elastin to form elastic fibers. In MFS, defects in microfibrils predispose individuals to thoracic aortic aneurysm (TAA), with ensuing vessel dissection and rupture (1, 2) .
The vascular defects in MFS were initially considered a consequence of constitutive tissue weakness due to structurally abnormal fibrillin-1 microfibrils (3). However, mouse models of MFS revealed that abnormal fibrillin-1 resulted in an increase in signaling by transforming growth factor beta (TGFβ), a cytokine involved in cell proliferation, differentiation, and matrix synthesis. TGFβ signaling requires the cytokine to bind its type II cell surface receptor (TβRII), which recruits and phosphorylates the type I receptor (TβRI). TβRI phosphorylates SMAD2/3 (mothers against decapentaplegic homolog 2/3), which forms a heterodimeric complex with SMAD4 and enters the nucleus to activate the transcription of TGFβ-dependent genes. The TGFβ-TβRI-TβRII complex also can activate MAPK signaling pathways, including ERK1 and ERK2 (ERK1/2) (4). The levels of both active SMAD2/3 and ERK1/2 are heightened in the ascending aortas of MFS mouse models (5-7). Treatment of these animals with TGFβ neutralizing antibodies (TGFβ-Nab) prevents or impedes TAA progression in some studies (6, 7) , while exacerbating arterial disease in others (5) .
TGFβ is secreted from cells as part of a biologically inactive large latent complex (LLC), composed of LTBP-1, -3, or -4, the prodomain dimer of TGFβ, referred to as the latency associated peptide (LAP), and the mature TGFβ dimer. LAP associates noncovalently with mature TGFβ to form the small latent complex (SLC). Covalent binding of the SLC to an LTBP occurs in the secretory pathway through the formation of two disulfide bonds between LAP and the third 8-Cys domain of LTBP-1, -3, or -4. Of the four LTBPs, LTBP-1 and -3 bind efficiently to all three TGFβ (TGFβ1, -2, and -3) LAP isoforms whereas LTBP-4 binds very inefficiently and only to TGFβ1 LAP (8, 9) . Moreover, LTBP-3 requires binding to TGFβ for secretion and is secreted only in the LLC form, suggesting an important role for LTBP-3 in the control of TGFβ availability (8, 9) .
LTBPs regulate TGFβ activity by facilitating its secretion, by localizing the LLC to specific sites in the ECM, and by participating in latent TGFβ release from the ECM (9) (10) (11) (12) . For TGFβ to bind to its receptor, the interaction of LAP and TGFβ must be disrupted, a process known as latent TGFβ activation (13, 14) . LTBP localization into the ECM is important for latent TGFβ activation. Abnormal localization is reported to alter TGFβ activity in both positive and negative ways: e.g., overexpression of a mutated form of LTBP-1 that binds TGFβ but does not interact with the ECM results in increased TGFβ activity (15) whereas mice in which the cysteines that link the propeptide of TGFβ1 to LTBP were mutated to serines, thereby blocking covalent interaction with LTBP and subsequent association to the ECM, have multiorgan inflammation resembling that observed in TGFβ1-null mice (16) . In addition, cleavage of LTBP-1 by a bone morphogenetic protein 1 (BMP1)-like metalloproteinase liberates LLC from the ECM and leads to activation of TGFβ1 by MMP2 (17) .
The mechanisms by which defective microfibrils perturb TGFβ signaling and cause aortic disease in MFS remain poorly understood. A current hypothesis proposes that abnormal fibrillin-1 fibers cause faulty LLC matrix incorporation, yielding increased TGFβ signaling with consequent aortic aneurysm and dissection (1, 2) . However, there is no evidence demonstrating either the Significance Marfan syndrome (MFS) is a connective tissue disorder caused by mutations of fibrillin-1 (FBN1), the main component of extracellular matrix microfibrils. FBN1 mutations predispose to thoracic aortic aneurysm and rupture and are associated with increased TGFβ signaling. TGFβ is secreted from cells complexed with latent TGFβ binding protein (LTBP), a protein that targets TGFβ to the ECM through interaction with fibrillin-1. One hypothesis proposes that aortic disease in MFS is due to the release of LTBP/TGFβ complexes in the aortic wall. We suppressed the expression of Ltbp3 in an MFS mouse model and observed essentially no aortic aneurysm and rupture in these compound mice. Our data suggest a key role for LTBP-3 in MFS aortic disease and provide a potential therapeutic point for intervention. participation of the LLC in MFS aortic disease or which LTBP is involved. We previously reported the in vitro and in vivo absence of LTBP-3, but not LTBP-1, incorporation into matrices that lack fibrillin-1 microfibrils, implying that LTBP-3 is the functionally important LTBP affecting latent TGFβ in MFS (18) . In the present study, we present data that identify LTBP-3 as an important contributor to TAA in MFS. (19, 20) . The mutant allele encodes a WT protein, but the animals produce only 10-20% of the normal amount of fibrillin-1 (19) . Survival studies were performed, and the mice were followed for 3 mo (Fig. 1A) :Ltbp3 −/− animals ( Fig. S1 ). Previous studies of Fbn1 mgR/mgR mice demonstrated progressive fragmentation of aortic elastic lamellae in the ascending aorta as the animals aged (19) . Histological analysis of sections from 2-mo-old Fbn1 mgR/mgR ascending aortas revealed disorganized media with extensive elastic fiber fragmentation ( Fig. 1 D and E). On the other hand, the aortic wall architecture and the number of elastic breaks were normalized in Fbn1 mgR/mgR mice lacking LTBP-3 ( Fig. 1 D and E) . In line with those observations, we observed a marked increased of the metalloelastase Mmp12 mRNA expression in Fbn1 mgR/mgR compared with Wt (Fig. S2 ). Absence of LTBP-3 in Fbn1 mgR/mgR significantly attenuated the expression of Mmp12 to a level of expression equivalent to Wt samples (Fig. S2 ). Together these data indicate that LTBP-3 absence in Fbn1 mgR/mgR mice preserves aortic elastic fiber integrity and protects against TAA and rupture. cultures with antibodies against both LTBP-3 and fibrillin-1 ( Fig.  2A) . In Fbn1 mgR/mgR and Fbn1 2B ). There was a 60% decrease in the intensity of the LTBP-3 band in Fbn1 mgR/mgR compared with Wt samples (Fig. 2B) . Immunoblotting with an antibody specific for LTBP-1 revealed no differences in the amount of protein released by cells of the four genotypes (Fig. 2B) . These experiments also revealed that, in nonreducing conditions, the molecular mass of the detected LTBP-3 band is consistent with that of the LTBP-3/LAP complex (Fig. 2B) , implying that the changes in LTBP-3 levels would also affect latent TGFβ incorporation.
Results

Genetic Deletion of
Next, we performed quantitative real-time PCR (qPCR) analyses to assess the relative levels of Fbn1 mRNA in the ascending aortas of the different genotypes. 
:Ltbp3
−/− samples, with no indication of an increase in FBN1 assembly in the absence of Ltbp3 (Fig. 2C) . mRNA levels of LTBP-1, -3, and -4 in the ascending aortas of the four genotypes were analyzed by qPCR (Fig. S4) . We observed similar levels of Ltbp1 and Ltbp4 transcripts in the four genotypes. Interestingly, there was a statistically significant increase in the mRNA level of Ltbp3 in Fbn1 mgR/mgR compared with Wt (Fig. S4) . The biological significance of this increase is unclear.
In summary, these data suggest that, in Fbn1 mgR/mgR ASMCs, the LLC composed of LTBP-3, LAP, and TGFβ is poorly incorporated into the matrix and abrogation of Ltbp3 expression in Fbn1 mgR/mgR mice prevents the formation of this complex and has no effect on FBN1 expression.
Absence of LTBP-3 Attenuates Activation of Smad2/3 and Erk1/2 in Fbn1 mgR/mgR Aortas. Increased ERK1/2 and Smad2/3 phosphorylation has been observed in the aortic wall in human tissues and in MFS mouse models (5, 7, 21) . Moreover, treatment of Fbn1 C1039G/-mice, a slowly progressing and mild form of MFS, with TGFβ-neutralizing antibodies, ERK1/2 inhibitor, or AT1r antagonists ameliorates the aortic phenotype in association with attenuated activation of Smad2/3 and ERK1/2 signaling (5, 7, 21). We therefore examined the effect of Ltbp3 deletion in Fbn1 mgR/mgR mice on ERK1/2 and Smad3 phosphorylation in the ascending aorta. We performed Western blotting analysis on ascending aorta lysates from 12-wk-old mice. Strong up-regulation of phospho-ERK1/2 (p-ERK1/2) was observed in Fbn1 mgR/mgR aortas compared with Wt or Ltbp3 −/− samples (Fig. 3A) . The absence of Ltbp3 in Fbn1 mgR/mgR mice suppressed ERK1/2 activation to levels indistinguishable from Wt (Fig. 3A) . Interestingly, we observed a small but significant decrease of ERK1/2 activation in Ltbp3 −/− ascending aortas compared with Wt tissues (Fig. 3A) . The significance of this change is unclear. Consistent with the Western blotting analysis, we observed, by immunostaining, increased p-ERK1/2 in the media of aortas from (Fig. 3B ). We also assessed TGFβ pathway signaling by measuring the levels of phosphorylated Smad3 (p-Smad3) in the ascending aortas of 11-wk-old mice. Western blotting analysis showed increased p-Smad3 in Fbn1 mgR/mgR compared with Wt or Ltbp3 −/− samples (Fig. 3A) . Absence of LTBP-3 in Fbn1 mgR/mgR mice resulted in a statistically significant reduction of Smad3 activation levels (Fig.  3A) . There was no significant difference in p-Smad3 levels between Fbn1 mgR/mgR :Ltbp3 −/− and Wt or Ltbp3 −/− tissues (Fig. 3A) . To assess TGFβ signaling with a different approach, we examined the expression levels of collagen 1 alpha1 (Col1a1), fibronectin (Fn), plasminogen-activator inhibitor-1 (Pai1), and connective tissue growth factor (Ctgf), four genes whose expression is often induced by TGFβ (22) . Col1a1, Fn, Pai1, and Ctgf expression were all significantly increased in the ascending aortas of Fbn1 mgR/mgR mice compared with Wt (Fig. 3C) mgR/mgR versus Wt samples identified 786 differentially expressed genes using a threshold of 1.5 and a corrected P value of <0.10 ( Fig. 4 and Dataset S1). However, in Fbn1 mgR/mgR :Ltbp3 −/− aortas, the expression of 773 genes out of 786 genes was reversed, and, as expected, two of the genes whose expression was not reversed were Fbn1 and Ltbp3 (Fig. 4 and Table  S1 ). There were no major mRNA expression changes in Ltbp3 −/− compared with Wt ascending aortas, except for Ltbp3 (>1.5-fold, corrected P value < 0.1) (Fig. 4 and Table S2 ). Overall, this result demonstrates that absence of LTBP-3 almost completely attenuates gene expression changes observed in MFS-like mice.
Upstream regulator analysis was applied to identify upstream molecular pathways that might explain the gene expression changes observed in Fbn1 mgR/mgR aortas. The 786 genes affected in Fbn1 mgR/mgR compared with Wt (>1.5-fold, P < 0.1) were analyzed with the Ingenuity Pathway Analysis (IPA) software package. This analysis confirmed the activation of the TGFβ pathway in Fbn1 mgR/mgR mice (upstream analysis Z-score, 5.734; P value, 1.4 E−37) (Table S3 ). However, the TGFβ pathway was not activated in Fbn1 mgR/mgR :Ltbp3 −/− ascending aortas because the expression of none of those genes regulated by TGFβ was significantly affected in these double mutants. Only Fbn1, a TGFβ gene target, was affected, but this result was expected because those mice are homozygous for a hypomorphic mutation in Fbn1. We additionally identified the activation of molecular signatures associated with inflammation, fibrosis, and immune function (Table S3) , which is consistent with reports that indicated the known participation of TGFβ in these processes (22, 23) .
Discussion
The purpose of the present study was to investigate the role of TGFβ/LTBP/fibrillin-1 interactions in the pathogenesis of TAA in MFS. A current view is that, in MFS, abnormal ECM sequestration of LTBP/TGFβ complexes due to defective fibrilin-1 microfibrils leads to increased TGFβ signaling and results in TAA (24) . However, the validity of this hypothesis and whether LTBP and latent TGFβ sequestration are involved in MFS have yet to be determined at a molecular level.
As an initial approach to analyze the interactions of LTBPs and fibrillin-1 in MFS, we previously examined the matrix assembly of LTBPs in aortic tissue from Fbn1-null mice (18) and found diminished ECM incorporation of LTBP-3 and, by inference, its bound TGFβ. In the present study, we extended this observation to ASMCs isolated from Wt and Fbn1 mgR/mgR mice (18, 20) . Fbn1 mgR/mgR mice represent a murine model that replicates the clinically severe and progressive form of human MFS, with death from aortic dissection and rupture during the first year of life accompanied by enhanced TGFβ signaling in the media of the thoracic aorta (19, 25) . As with Fbn1 −/− ASMCs, Fbn1 mgR/mgR cells exhibited impaired LTBP-3 incorporation into the matrix with no significant change in LTBP-1 incorporation.
To test the role of LTBP-3 in the aortic disease observed in MFS, we generated mice containing mutations in both Fbn1 (Fbn1 mgR/mgR ) and Ltbp3 genes. We reasoned that, if enhanced activation of latent TGFβ complexes containing LTBP-3 were causative for the vascular disease in MFS, the absence of LTBP-3 should prevent the formation of the LLC that contributes to pathological TGFβ signaling and thus attenuate aortic disease progression in Fbn1 mgR/mgR . Ltbp3 deletion dramatically reduced aortic disease in Fbn1 mgR/mgR mice and increased their survival to a level similar to that of Wt mice. Fbn1 mgR/mgR ;Ltbp3 −/− mice had aortas with diameters equivalent to those of normal mice, the number of discontinuities in the elastic lamellae was decreased by 80%, signaling through both Smad3 and ERK1/2 pathways was normalized, and expression of two genes regulated by TGFβ was reverted to levels approximating that observed in WT mice.
To our knowledge, this work is the first study in which ablation of a gene involved in the regulation of TGFβ action improves the aortic disease phenotype in MFS mice. Genetic ablation of Mmp2 results in prolonged survival of Fbn1 mgR/mgR mice, but it is uncertain whether this finding reflects a diminution of TGFβ signaling due to the absence of proteolytic activation of latent TGFβ by MMP2 or is a consequence of decreased aortic media degeneration caused by MMP2 enzymatic activity (25) . Conversely, mutations in several genes that encode components of the TGFβ pathway either alone or in combination with an MFS mouse model (e.g., loss-of-function mutations in Tgfbr1 or Tgfbr2 genes, Smad3-null mutation, and Smad4 or Tgfb2 haploinsufficiency in Fbn1 C1039G/+ mice) either induce or worsen TAA (7, (26) (27) (28) (29) (30) . Curiously, these mutations are expected to attenuate TGFβ signaling but yield paradoxical activation of TGFβ signaling in the aortas. However, deletion of Ltbp3 in Fbn1 mgR/mgR mice did not result in paradoxical increase in TGFβ signaling and prevented aortic disease in Fbn1 mgR/mgR mice although LTBP-3 deletion is expected to decrease TGFβ levels and accordingly to worsen aortic disease (31) .
A possible explanation for these discrepancies is that, whereas Tgfbr1 and -2 mutations, Smad3 deletion, and Smad4 haploinsufficiency affect signaling of all three TGFβ isoforms, Ltbp3 deletion disturbs only the subset of latent TGFβ molecules bound to this specific carrier protein. It should be noted that our results also indicate that LTBP-1 present in the aorta cannot compensate for the loss of LTBP-3 even though both molecules bind all three isoforms of TGFβ. This observation implies functional specificity for these two LTBPs. It is still unclear which TGFβ isoform is the mediator of the aortic disease found in MFS because LTBP-3 interacts with TGFβ1, -β2, and -β3 isoforms with similar efficiency (9) . However, it is unlikely that ablation of Ltbp3 in Fbn1 mgR/mgR mice diminished TGFβ2 signaling because mice with Tgfb2 haploinsufficiency, when bred with Fbn1 C1039G/+ mice, display increased aortic dilatation and morbidity, indicating a protective role for TGFβ2 (28) . Accordingly, we propose that specifically lowering either TGFβ1 or -3 in MFS mice should mitigate TAA and rupture.
To date, only pharmacological inhibition of TGFβ with either TGFβ-neutralizing antibodies (Nabs), the MEK1/2 inhibitor RDEA119, the angiotensin-II type 1 receptor-blocker losartan, or doxycycline ameliorates the aortic phenotype in MFS mice (6, 7, 25, 32) . However, it is unclear whether the efficacy of losartan or doxycycline in attenuating aortic disease in MFS mice is due to direct impairment of TGFβ signaling or whether TGFβ-independent mechanisms are involved (5, 25) . Pharmacological inhibition of TGFβ with neutralizing antibodies has also underscored the complex, controversial, and context-dependent roles of TGFβ in aneurysm. Whereas earlier studies of systemic TGFβ neutralization with the Fbn1 C1039G/+ mouse model prevented TAA formation, recent results with the Fbn1 mgR/mgR mouse model have indicated that TGFβ can exert opposite effects on TAA pathology that broadly correlate with the early and late stages of TAA progression (5). Thus, early treatment (postnatal day 16; P16) with TGFβ-neutralizing antibodies enhances aneurysm formation whereas later treatment (P45) diminishes aneurysm formation. This context-dependent role of TGFβ was also underscored by a recent study in which induction of aortic dissection was dependent on the age at which Tgfbr2 was ablated in smooth muscle cells, with enhanced incidence of the phenotype with young mice and almost no in cidence after 9 wk (33). Differential contributions of TGFβ signaling to aortic physiology early and later after birth may explain the greater incidence of aortic dissection in young mice upon targeted ablation of Tgfbr2 in smooth muscle cells (33) . Accordingly, we propose that the protective effect of LTBP-3 loss might represent the specific diminution of the pathological effects of LTBP-3/TGFβ complexes during aortic disease with no perturbation of basal physiological TGFβ signaling involved in aorta development or aortic tissue homeostasis and repair pathways (33, 34) . In support of this postulate, we have not observed any evidence of vascular phenotype in this study or other studies with Ltbp3 −/− mice (31, 35) . Finally, we cannot exclude the possibility that LTBP-3 has TGFβ-independent functions that participate in aortic pathology. TGFβ-independent activities have been identified for LTBP-4 in stabilizing microfibril bundles and regulating elastic fiber assembly and for LTBP-2 in the development of ciliary zonule microfibrils (36) (37) (38) . Thus, LTBP-3 might directly contribute to the integrity of the matrix or the mechanical compliance of the aortic wall (39) .
In summary, our work addresses the significance of the interaction between LTBP and fibrillin-1 microfibrils in the control of TGFβ action by using a genetic approach. Our results demonstrate the potential importance of the interaction between the LTBP-3/TGFβ complex and fibrillin-1 microfibrils in the control of detrimental TGFβ signaling involved in TAA pathogenesis in MFS. Blocking activation of latent TGFβ associated with LTBP-3 might represent a potentially novel and specific therapeutic approach to preventing aortic disease in MFS. 
